Screening for Cardiovascular Safety: A Structure−Activity Approach for Guiding Lead Selection of Melanin Concentrating Hormone Receptor 1 Antagonists
Citations Over TimeTop 17% of 2006 papers
Abstract
An inactin-anesthetized rat cardiovascular (CV) assay was employed in a screening mode to triage multiple classes of melanin-concentrating hormone receptor 1 (MCHr1) antagonists. Lead identification was based on a compound profile producing high drug concentration in both plasma (>40 μM) and brain (>20 μg/g) with <15% change in cardiovascular endpoints. As a result of these stringent requirements, lead optimization activities on multiple classes of MCHr1 antagonists were terminated. After providing evidence that the cardiovascular liabilities were not a function of MCHr1 antagonism, continued screening identified the chromone-substituted aminopiperidine amides as a class of MCHr1 antagonists that demonstrated a safe cardiovascular profile at high drug concentrations in both plasma and brain. The high incidence of adverse cardiovascular effects associated with an array of MCHr1 antagonists of significant chemical diversity, combined with the stringent safety requirements for antiobesity drugs, highlight the importance of incorporating cardiovascular safety assessment early in the lead selection process.
Related Papers
- → pH Controlled Release of Chromone from Chromone-Fe3O4 Nanoparticles(2008)158 cited
- → Current Strategies in Development of New Chromone Derivatives with Diversified Pharmacological Activities: A Review(2020)105 cited
- → Design, Synthesis and Antiviral Activity of 2-(3-Amino-4-piperazinylphenyl)chromone Derivatives(2013)15 cited
- Study on Chromones of Aquilariae Lignum Resinatum(2011)
- → ChemInform Abstract: Design, Synthesis and Antiviral Activity of 2‐(3‐Amino‐4‐piperazinylphenyl)chromone Derivatives.(2013)